Samus Therapeutics Launches Phase 1 Trial of Tau-targeting Therapy

Samus Therapeutics Launches Phase 1 Trial of Tau-targeting Therapy
Following the approval of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), Samus Therapeutics is launching a Phase 1 trial in the United States to evaluate the safety of its investigational therapy PU-AD, an epichaperome inhibitor, for the treatment of Alzheimer’s disease. The trial, which will be carried out at a center in Texas, is recruiting participants. More information about enrollment can be found here. Characteristic features of Alzheimer's, such as disrupted communication between nerve cells, are partly caused by the presence of abnormal aggregates of two proteins — called beta-amyloid and tau — in the brain. Tau proteins are necessary components of healthy brain nerve cells, but in Alzheimer’s, this protein undergoes chemical modifications — a process called hyperphosphorylation — that make tau stick to other tau proteins, forming a complex known as tau tangles. Protein complexes known as epichaperomes (or stress chaperomes) prevent the degradation of aberrant proteins such as tau, allowing their aggregation. PU-AD, developed by Samus Therapeutics, is an oral, brain-permeable investigational therapy for Alzheimer's that specifically inhibits epichaperomes, thus allowing the removal of tau tangles. Previous evidence from preclinical studies suggests that epichaperomes contribute to and may even initiate neurodegenerative diseases, such as Alzheimer's. Inhibiting their activity with PU-AD allowed ab
Subscribe or to access all post and page content.